Blueberry are delighted to welcome Mr. Andrew Kay to Blueberry Therapeutics as Chairman of the Board. Andrew brings more than 30 years of commercial and leadership experience in the pharmaceutical sector, latest as CEO of Algeta ASA. During Andrew’s leadership, Algeta’s lead product, Xofigo, was approved by the FDA and EMA for the treatment of bone metastases in castration resistant prostate cancer patients. In February 2014, Algeta was acquired by its partner Bayer AG for USD 2.9 billion. Andrew’s previous roles include Global Head of Marketing and Sales and a Member of the Healthcare Committee and Pharmaceutical Executive Committee at Novartis, and several other senior commercial positions in Europe and the USA with AstraZeneca, Eli Lilly, Sandoz and Boots.